Health Assessment Questionnaire disability progression in early rheumatoid arthritis: Systematic review and analysis of two inception cohorts

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 2, 2014, Pages 131-144

  Norton, Sam ^a   Fu, Bo ^b   Scott, David L ^c   Deighton, Chris ^d   Symmons, Deborah P M ^b,e   Wailoo, Allan J ^f   Tosh, Jonathan ^f   Lunt, Mark ^b   Davies, Rebecca ^b   Young, Adam ^g   Verstappen, Suzanne M M ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d ROYAL DERBY HOSPITAL   (United Kingdom)

^e MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

^g St Albans City Hospital   (United Kingdom)

Author keywords

Health Assessment Questionnaire; Inflammatory polyarthritis; Latent class growth model; Predictors; Rheumatoid arthritis; Systematic review

Indexed keywords

RHEUMATOID FACTOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; METHOTREXATE;

AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; DAS28; DISABILITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FUNCTIONAL ASSESSMENT; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SEX RATIO; UNITED KINGDOM; ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; COHORT ANALYSIS; FEMALE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; QUESTIONNAIRE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COHORT STUDIES; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; GREAT BRITAIN; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; PROSPECTIVE STUDIES; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84927522368     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.05.003     Document Type: Article

References (75)

1. Lillegraven S., Kvien T.K. Measuring disability and quality of life in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007, 21:827-840.
2. Smolen J.S., Aletaha D. Patients with rheumatoid arthritis in clinical care. Ann Rheum Dis 2004, 63:221-225.
3. Farragher T.M., Lunt M., Bunn D.K., Silman A.J., Symmons D.P. Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis 2007, 66:486-492.
4. Sokka T., Hakkinen A., Krishnan E., Hannonen P. Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. Ann Rheum Dis 2004, 63:494-497.
5. Bombardier C., Barbieri M., Parthan A., Zack D.J., Walker V., Macarios D., et al. The relationship between joint damage and functional disability in rheumatoid arthritis: a systematic review. Ann Rheum Dis 2012, 71:836-844.
6. Verstappen S.M., Bijlsma J.W., Verkleij H., Buskens E., Blaauw A.A., ter Borg E.J., et al. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum 2004, 51:488-497.
7. Young A., Dixey J., Kulinskaya E., Cox N., Davies P., Devlin J., et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis 2002, 61:335-340.
8. Welsing P.M., van Gestel A.M., Swinkels H.L., Kiemeney L.A., van Riel P.L. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001, 44:2009-2017.
9. Hazes J.M. Determinants of physical function in rheumatoid arthritis: association with the disease process. Rheumatology (Oxford) 2003, 42(Suppl. 2):ii17-ii21.
10. Drossaers-Bakker K.W., de B.M., van Z.D., Zwinderman A.H., Breedveld F.C., Hazes J.M. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999, 42:1854-1860.
11. Bansback N., Young A., Brennan A., Dixey J. A prognostic model for functional outcome in early rheumatoid arthritis. J Rheumatol 2006, 33:1503-1510.
12. Young A., Dixey J., Cox N., Davies P., Devlin J., Emery P., et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology (Oxford) 2000, 39:603-611.
13. Combe B., Cantagrel A., Goupille P., Bozonnat M.C., Sibilia J., Eliaou J.F., et al. Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritis. J Rheumatol 2003, 30:2344-2349.
14. Wiles N., Dunn G., Barrett E., Silman A., Symmons D. Associations between demographic and disease-related variables and disability over the first five years of inflammatory polyarthritis: a longitudinal analysis using generalized estimating equations. J Clin Epidemiol 2000, 53:988-996.
15. Guillemin F., Suurmeijer T., Krol B., Bombardier C., Briancon S., Doeglas D., et al. Functional disability in early rheumatoid arthritis: description and risk factors. J Rheumatol 1994, 21:1051-1055.
16. Quinn M.A., Gough A.K., Green M.J., Devlin J., Hensor E.M., Greenstein A., et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) 2006, 45:478-480.
17. Bansback N., Marra C.A., Finckh A., Anis A. The economics of treatment in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009, 23:83-92.
18. Scott D.L., Pugner K., Kaarela K., Doyle D.V., Woolf A., Holmes J., et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:122-132.
19. Gardiner P.V., Sykes H.R., Hassey G.A., Walker D.J. An evaluation of the Health Assessment Questionnaire in long-term longitudinal follow-up of disability in rheumatoid arthritis. Br J Rheumatol 1993, 32:724-728.
20. Michaud K., Wallenstein G., Wolfe F. Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: a longitudinal study of 18,485 patients. Arthritis Care Res (Hoboken) 2011, 63:366-372.
21. Harrison M.J., Farragher T.M., Clarke A.M., Manning S.C., Bunn D.K., Symmons D.P. Association of functional outcome with both personal- and area-level socioeconomic inequalities in patients with inflammatory polyarthritis. Arthritis Rheum 2009, 61:1297-1304.
22. Marra C.A., Lynd L.D., Esdaile J.M., Kopec J., Anis A.H. The impact of low family income on self-reported health outcomes in patients with rheumatoid arthritis within a publicly funded health-care environment. Rheumatology (Oxford) 2004, 43:1390-1397.
23. Scott D.L., Smith C., Kingsley G. Joint damage and disability in rheumatoid arthritis: an updated systematic review. Clin Exp Rheumatol 2003, 21:S20-S27.
24. Norton S., Sacker A., Dixey J., Done J., Williams P., Young A., et al. Trajectories of functional limitation in early rheumatoid arthritis and their association with mortality. Rheumatology (Oxford) 2013, 52:2016-2024.
25. Young A. Short-term outcomes in recent-onset rheumatoid arthritis. Br J Rheumatol 1995, 34(Suppl. 2):79-86.
26. Symmons D.P., Barrett E.M., Bankhead C.R., Scott D.G., Silman A.J. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 1994, 33:735-739.
27. Wiles N.J., Dunn G., Barrett E.M., Harrison B.J., Silman A.J., Symmons D.P. One year followup variables predict disability 5 years after presentation with inflammatory polyarthritis with greater accuracy than at baseline. J Rheumatol 2000, 27:2360-2366.
28. Kirwan J.R., Reeback J.S. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986, 25:206-209.
29. Nagin D.S., Tremblay R.E. Analyzing developmental trajectories of distinct but related behaviors: a group-based method. Psychol Methods 2001, 6:18-34.
30. van Zeben D., Hazes J.M., Zwinderman A.H., Cats A., Schreuder G.M., D'Amaro J., et al. Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a followup study. Arthritis Rheum 1991, 34:822-830.
31. Wolfe F., Hawley D.J., Cathey M.A. Clinical and health status measures over time: prognosis and outcome assessment in rheumatoid arthritis. J Rheumatol 1991, 18:1290-1297.
32. Munro R., Hampson R., McEntegart A., Thomson E.A., Madhok R., Capell H. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. Ann Rheum Dis 1998, 57:88-93.
33. Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum 2000, 43:2751-2761.
34. Kroot E.J., van Leeuwen M.A., van Rijswijk M.H., Prevoo M.L., van 't Hof M.A., van de Putte L.B., et al. No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann Rheum Dis 2000, 59:954-958.
35. Ahlmen M., Svensson B., Albertsson K., Forslind K., Hafstrom I. Influence of gender on assessments of disease activity and function in early rheumatoid arthritis in relation to radiographic joint damage. Ann Rheum Dis 2010, 69:230-233.
36. Benton N., Stewart N., Crabbe J., Robinson E., Yeoman S., McQueen F.M. MRI of the wrist in early rheumatoid arthritis can be used to predict functional outcome at 6 years. Ann Rheum Dis 2004, 63:555-561.
37. Persson L.O., Larsson B.M., Nived K., Eberhardt K. The development of emotional distress in 158 patients with recently diagnosed rheumatoid arthritis: a prospective 5-year follow-up study. Scand J Rheumatol 2005, 34:191-197.
38. Proudman S.M., Keen H.I., Stamp L.K., Lee A.T., Goldblatt F., Ayres O.C., et al. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Semin Arthritis Rheum 2007, 37:99-111.
39. Courvoisier N., Dougados M., Cantagrel A., Goupille P., Meyer O., Sibilia J., et al. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. Arthritis Res Ther 2008, 10:R106.
40. Farragher T.M., Lunt M., Fu B., Bunn D., Symmons D.P. Early treatment with, and time receiving, first disease-modifying antirheumatic drug predicts long-term function in patients with inflammatory polyarthritis. Ann Rheum Dis 2010, 69:689-695.
41. Benka J., Nagyova I., Rosenberger J., Calfova A., Macejova Z., Middel B., et al. Social support and psychological distress in rheumatoid arthritis: a 4-year prospective study. Disabil Rehabil 2012, 34:754-761.
42. Fries J.F., Spitz P.W., Young D.Y. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982, 9:789-793.
43. Sherrer Y.S., Bloch D.A., Mitchell D.M., Young D.Y., Fries J.F. The development of disability in rheumatoid arthritis. Arthritis Rheum 1986, 29:494-500.
44. Wolfe F., Cathey M.A. The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol 1991, 18:1298-1306.
45. Epstein W.V., Henke C.J., Yelin E.H., Katz P.P. Effect of parenterally administered gold therapy on the course of adult rheumatoid arthritis. Ann Intern Med 1991, 114:437-444.
46. Hawley D.J., Wolfe F. Sensitivity to change of the health assessment questionnaire (HAQ) and other clinical and health status measures in rheumatoid arthritis: results of short-term clinical trials and observational studies versus long-term observational studies. Arthritis Care Res 1992, 5:130-136.
47. Leigh J.P., Fries J.F., Parikh N. Severity of disability and duration of disease in rheumatoid arthritis. J Rheumatol 1992, 19:1906-1911.
48. Guillemin F., Briancon S., Pourel J. Functional disability in rheumatoid arthritis: two different models in early and established disease. J Rheumatol 1992, 19:366-369.
49. Ward M.M., Leigh J.P. Marital status and the progression of functional disability in patients with rheumatoid arthritis. Arthritis Rheum 1993, 36:581-588.
50. Leigh J.P., Fries J.F. Tobit, fixed effects, and cohort analyses of the relationship between severity and duration of rheumatoid arthritis. Soc Sci Med 1993, 36:1495-1502.
51. Lassere M., Wells G., Tugwell P., Edmonds J. Percentile curve reference charts of physical function: rheumatoid arthritis population. J Rheumatol 1995, 22:1241-1246.
52. Ward M.M., Lubeck D., Leigh J.P. Longterm health outcomes of patients with rheumatoid arthritis treated in managed care and fee-for-service practice settings. J Rheumatol 1998, 25:641-649.
53. Clarke A.E., St-Pierre Y., Joseph L., Penrod J., Sibley J.T., Haga M., et al. Radiographic damage in rheumatoid arthritis correlates with functional disability but not direct medical costs. J Rheumatol 2001, 28:2416-2424.
54. Gordon P., West J., Jones H., Gibson T. A 10 year prospective followup of patients with rheumatoid arthritis 1986-96. J Rheumatol 2001, 28:2409-2415.
55. Hurst S., Kallan M.J., Wolfe F.J., Fries J.F., Albert D.A. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects. J Rheumatol 2002, 29:1639-1645.
56. Krishnan E., Fries J.F. Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998: a longitudinal study of 3035 patients. Am J Med 2003, 115:371-376.
57. Krishnan E., Tugwell P., Fries J.F. Percentile benchmarks in patients with rheumatoid arthritis: Health Assessment Questionnaire as a quality indicator (QI). Arthritis Res Ther 2004, 6:R505-R513.
58. Demange V., Guillemin F., Baumann M., Suurmeijer T.P., Moum T., Doeglas D., et al. Are there more than cross-sectional relationships of social support and support networks with functional limitations and psychological distress in early rheumatoid arthritis? the European Research on Incapacitating Diseases and Social Support Longitudinal Study. Arthritis Rheum 2004, 51:782-791.
59. Baddoura R., Haddad S., Awada H., Al-Masri A.F., Merheb G., Attoui S., et al. Severity of rheumatoid arthritis: the SEVERA study. Clin Rheumatol 2006, 25:700-704.
60. Sokka T., Kautiainen H., Hannonen P., Pincus T. Changes in Health Assessment Questionnaire disability scores over five years in patients with rheumatoid arthritis compared with the general population. Arthritis Rheum 2006, 54:3113-3118.
61. Shinozaki M., Inoue E., Nakajima A., Hara M., Tomatsu T., Kamatani N., et al. Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. Mod Rheumatol 2007, 17:403-408.
62. Odegard S., Finset A., Mowinckel P., Kvien T.K., Uhlig T. Pain and psychological health status over a 10-year period in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2007, 66:1195-1201.
63. Gonzalez-Alvaro I., Descalzo M.A., Carmona L. Trends towards an improved disease state in rheumatoid arthritis over time: influence of new therapies and changes in management approach: analysis of the EMECAR cohort. Arthritis Res Ther 2008, 10:R138.
64. Ranganath V.K., Paulus H.E., Onofrei A., Khanna D., Reed G., Elashoff D.A., et al. Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database. J Rheumatol 2008, 35:1966-1971.
65. Iikuni N., Sato E., Hoshi M., Inoue E., Taniguchi A., Hara M., et al. The influence of sex on patients with rheumatoid arthritis in a large observational cohort. J Rheumatol 2009, 36:508-511.
66. Bazzani C., Filippini M., Caporali R., Bobbio-Pallavicini F., Favalli E.G., Marchesoni A., et al. Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: clinical outcomes. Autoimmun Rev 2009, 8:260-265.
67. Wolfe F., Michaud K. The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. Arthritis Res Ther 2010, 12:R35.
68. Staples M.P., March L., Lassere M., Reid C., Buchbinder R. Health-related quality of life and continuation rate on first-line anti-tumour necrosis factor therapy among rheumatoid arthritis patients from the Australian Rheumatology Association Database. Rheumatology (Oxford) 2011, 50:166-175.
69. Bjork M., Trupin L., Thyberg I., Katz P., Yelin E. Differences in activity limitation, pain intensity, and global health in patients with rheumatoid arthritis in Sweden and the USA: a 5-year follow-up. Scand J Rheumatol 2011, 40:428-432.
70. Iikuni N., Inoue E., Tanaka E., Hara M., Tomatsu T., Kamatani N., et al. Low disease activity state with corticosteroid may not represent "true" low disease activity state in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:519-521.
71. Shidara K., Inoue E., Hoshi D., Sato E., Nakajima A., Momohara S., et al. Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan. Rheumatol Int 2012, 32:361-366.
72. Wolfe F., Cathey M.A. The effect of age on methotrexate efficacy and toxicity. J Rheumatol 1991, 18:973-977.
73. Leigh J.P., Fries J.F. Predictors of disability in a longitudinal sample of patients with rheumatoid arthritis. Ann Rheum Dis 1992, 51:581-587.
74. Radner H., Smolen J.S., Aletaha D. Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. Rheumatology (Oxford) 2011, 50:381-388.
75. Cho S.K., Sung Y.K., Choi C.B., Cha H.S., Choe J.Y., Chung W.T., et al. Do patients with elderly-onset rheumatoid arthritis have severe functional disability?. Semin Arthritis Rheum 2012, 42:23-31.